| UCSF Magazine

3 UCSF Scientists Are Elected to the National Academy of Sciences

Neurosurgeon Edward Chang, MD, developmental geneticist Thomas Kornberg, PhD, and virologist Raul Andino-Pavlovsky, PhD, have been elected to the National Academy of Sciences (NAS), one of the highest honors in American science.

AI in Cancer Care, Targeted Therapies Among Cancer Conference Talks

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat cancers and other cancer research topics at this year’s annual meeting of the American Association for Cancer Research (AACR) conference, held April 25-30 in Chicago.

Breakthrough Multiple Sclerosis Therapy by UCSF Doctor Transforms Treatment for Millions

What Is Tdap? Here’s What You Need To Know To Stay Protected Against Whooping Cough

UCSF Police Department Chief of Staff Helps Others Feel Heard, Valued

Ailene Estalilla is all about uplifting others. The chief of staff at the UCSF Police Department and mother of three does it every day, at work and at home.

New and Easier Way to Monitor Inflammatory Bowel Disease in Kids

This spring, UCSF Benioff Children's Hospital Walnut Creek Outpatient Cetner will become one of the only children's hospital on the West Coast to have an intestinal ultrasound (IUS) machine for children with IBD, making for a much better patient experience.

UCSF Health Hospitals Earn Top Honors for Patient Safety

Three UCSF Health hospitals received “A” ratings in the spring 2025 Hospital Safety Grades from The Leapfrog Group, an independent national nonprofit watchdog focused on patient safety.

How Do Neighborhoods Impact Children’s Chances of Surviving Leukemia?

A study established new neighborhood characteristics that lead to higher death rates in children with leukemia that can serve as intervention opportunities.

Diabetes Medication May Increase Risk of Perioperative Ketoacidosis

Sodium-glucose cotransporter-2 inhibitors (SGLT2i), or gliflozins, are medications used in the treatment of type 2 diabetes mellitus (T2DM). They are designed to lower high blood glucose levels typical in T2DM, and work by inhibiting the sodium-glucose transport protein 2. SGLT2i have also been shown to improve outcomes among patients with chronic kidney disease, heart failure and coronary artery disease.

How ‘Magic Mushrooms’ Could Help Parkinson’s Disease Patients

A first-of-its-kind study tested the safety of psilocybin on patients with mild to moderate Parkinson’s disease and found that patients experienced clinically significant improvements in mood, cognition, and motor function that lasted for weeks after the drug was out of their systems.

Subscribe to